Methotrexat Ebewe

Methotrexate, the active ingredient in Methotrexat Ebewe, is an antimetabolite presented as an intravenous formulation for injection use. It belongs to the antineoplastic/immunosuppressant class and is indicated for conditions such as rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and osteosarcoma.

GNH USA supplies Methotrexat Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring quality assurance and regulatory conformity across all markets. The company provides dedicated logistics, documentation support, and post‑delivery service to meet the needs of clinical and procurement teams.

Methotrexate is employed across several disease categories, primarily as an antimetabolite that interferes with rapidly dividing cells and modulates immune activity.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: limits skin cell proliferation, improving plaque severity. - Acute lymphoblastic leukemia: inhibits malignant lymphoblast growth, supporting remission. - Non‑Hodgkin lymphoma: disrupts cancer cell replication, aiding therapeutic response. - Osteosarcoma: impedes tumor cell division, contributing to multimodal treatment.

Adverse reactions may occur with methotrexate therapy.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Mild elevation of liver enzymes. - Transient low white blood cell count.

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infection due to profound bone‑marrow suppression. - Renal impairment or failure. - Severe cutaneous reactions such as Stevens‑Johnson syndrome. - Myelosuppression leading to pancytopenia.

Methotrexat Ebewe requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); avoid use in pregnant or nursing patients. - Liver function: monitor enzymes regularly; discontinue if significant elevation occurs. - Hematology: perform complete blood counts before and during therapy to detect cytopenias. - Renal function: assess creatinine clearance; adjust or avoid in severe renal impairment. - Infection risk: postpone dosing in the presence of active infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate may interact with several medicines, necessitating vigilance.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and other antibiotics: heighten risk of bone‑marrow suppression. - Sulfonamides: potentiate hematologic adverse effects. - Live vaccines: risk of severe infection due to immunosuppression. - Other folate antagonists: additive toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Azathioprine or mycophenolate: combined immunosuppression, watch blood counts. - Allopurinol: can raise methotrexate levels, adjust dose if needed. - Proton pump inhibitors: may affect renal clearance, monitor renal function.